Allogene Therapeutics (ALLO) Other financing activities (2018 - 2026)

Allogene Therapeutics has reported Other financing activities for 8 years, with the latest figure at $450000.0 in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $450000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (up 91.86% YoY) and the FY2025 annual result came in at $6.9 million, up 749.69% from the prior year.
• Other financing activities declined to $450000.0 in Q1 2026 per ALLO's latest filing, from $6.3 million in the prior quarter.
• Over five years, Other financing activities peaked at $6.3 million in Q3 2025 and troughed at -$2.0 million in Q4 2022.
• A 5-year average of $1.3 million and a median of $856000.0 in 2024 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2022 and 2025: Other financing activities sank 123.12% in 2022, then surged 823.42% in 2025.
• Over 5 years, Other financing activities stood at -$2.0 million in 2022, then surged by 205.83% to $2.1 million in 2023, then increased by 10.21% to $2.3 million in 2024, then jumped by 172.61% to $6.3 million in 2025, then tumbled by 92.82% to $450000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $450000.0, $6.3 million, and $638000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.